drugset / Trial / NCT01146171
Japanese Phase 1 Study of BMS-844203 (CT322)
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this clinical study is to evaluate the safety and tolerability of CT-322 monotherapy to determine the recommended dose for phase II and subsequent studies
Timeline
- Start
- 2013-11
- Primary completion
- 2015-01
- Completion
- 2015-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | PEGDINETANIB | Protein / enzyme biologic | 1 mg/kg | Intravenous |
| Subject | PEGDINETANIB | Protein / enzyme biologic | 2 mg/kg | Intravenous |